211 related articles for article (PubMed ID: 23864926)
1. Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness.
Lang DJ; Barr AM; Procyshyn RM
Curr Cardiovasc Risk Rep; 2013 Aug; 7(4):283-287. PubMed ID: 23864926
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
4. Cardiometabolic management in severe mental illness requiring an atypical antipsychotic.
Schmitz A; Rohrich M; Newman W; Wolf P
Ment Health Clin; 2017 Mar; 7(2):81-87. PubMed ID: 29955503
[TBL] [Abstract][Full Text] [Related]
5. Consequences of Antipsychotic Medications on Mental Health.
Bukhari SNA
Curr Drug Saf; 2022; 17(4):285-293. PubMed ID: 35170421
[TBL] [Abstract][Full Text] [Related]
6. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
7. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
Maher AR; Theodore G
J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
[TBL] [Abstract][Full Text] [Related]
8. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
Moteshafi H; Zhornitsky S; Brunelle S; Stip E
Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
[TBL] [Abstract][Full Text] [Related]
9. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
10. General practice pharmacist-led antipsychotic physical health monitoring: a prospective intervention scoping study.
Johnson CF; Ingram F; Thomson F; Srireddy P; Jani BD; Greenlaw N
Fam Pract; 2024 Feb; 41(1):41-49. PubMed ID: 38180874
[TBL] [Abstract][Full Text] [Related]
11. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis.
Vancampfort D; Stubbs B; Mitchell AJ; De Hert M; Wampers M; Ward PB; Rosenbaum S; Correll CU
World Psychiatry; 2015 Oct; 14(3):339-47. PubMed ID: 26407790
[TBL] [Abstract][Full Text] [Related]
12. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.
Correll CU; Robinson DG; Schooler NR; Brunette MF; Mueser KT; Rosenheck RA; Marcy P; Addington J; Estroff SE; Robinson J; Penn DL; Azrin S; Goldstein A; Severe J; Heinssen R; Kane JM
JAMA Psychiatry; 2014 Dec; 71(12):1350-63. PubMed ID: 25321337
[TBL] [Abstract][Full Text] [Related]
13. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
[TBL] [Abstract][Full Text] [Related]
14. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
[TBL] [Abstract][Full Text] [Related]
15. Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT.
Crawford MJ; Thana L; Evans R; Carne A; O'Connell L; Claringbold A; Saravanamuthu A; Case R; Munjiza J; Jayacodi S; Reilly JG; Hughes E; Hoare Z; Barrett B; Leeson VC; Paton C; Keown P; Pappa S; Green C; Barnes TR
Health Technol Assess; 2020 Sep; 24(44):1-54. PubMed ID: 32930090
[TBL] [Abstract][Full Text] [Related]
16. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders
Aust N Z J Psychiatry; 2005; 39(1-2):1-30. PubMed ID: 15660702
[TBL] [Abstract][Full Text] [Related]
17. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.
Edinoff A; Ruoff MT; Ghaffar YT; Rezayev A; Jani D; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2020 Sep; 50(4):83-117. PubMed ID: 33012874
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses.
Henderson DC; Vincenzi B; Andrea NV; Ulloa M; Copeland PM
Lancet Psychiatry; 2015 May; 2(5):452-464. PubMed ID: 26360288
[TBL] [Abstract][Full Text] [Related]
19. [About the association between antipsychotic medication and cardiovascular morbidity: epidemiology and possible background mechanisms].
Gaszner G; Barna G; Dome P
Neuropsychopharmacol Hung; 2017 Jun; 19(2):106-116. PubMed ID: 28918419
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
